Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

You are viewing this page in draft mode.

Trial watch

The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors.
Figure 2: Recruitment rates for trials involving anti-PD1/PDL1 therapies.

Acknowledgements

The authors thank D. Patel from IQVIA for supporting this report.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Jun Tang.

Ethics declarations

Competing interests

JT, JXY, and VHL are employees of Cancer Research Institute and claim no conflicts of interests.

STN, JPH, YL and DP are employees of IQVIA and claim no conflicts of interests.

Supplementary information

Supplementary information

Supplementary information S1 (figure) (PDF 577 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tang, J., Yu, J., Hubbard-Lucey, V. et al. The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nat Rev Drug Discov 17, 854–855 (2018). https://doi.org/10.1038/nrd.2018.210

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing